BevaciRel (Bevacizumab) is a recombinant humanized monoclonal IgG1 antibody that binds and inhibits biological activity of human vascular endothelial growth factor (VEGF). Bevacizumab contains human framework regions and the complementary determining regions of a murine antibody.

Molecular weight of BevaciRel is 149 kDa. Bevacizumab has been approved for Metastatic Colorectal Cancer (mCRC), Non-Squamous Non-Small Cell Lung Cancer (NSCLC), Glioblastoma, Metastatic Renal Cell Carcinoma (mRCC), Persistent, Recurrent, or Metastatic Carcinoma of the Cervix, and Platinum-Resistant Recurrent Epithelial Ovarian, Fallopian Tube, Or Primary Peritoneal Cancer

BevaciRel is available as a clear, sterile solution of 100 mg/4ml single use vial and 400 mg/16ml single use vial for infusion